Investors & Media
We are a clinical stage chemoprotection oncology company focused on developing medicines to make chemotherapy safer and thereby more effective to save more patients’ lives.
ALRN-6924, our first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the only reported chemoprotective agent in clinical development to employ a biomarker strategy, focusing exclusively on treating patients with p53-mutated cancers.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
February 21, 2023Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives
November 30, 2022Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements
November 10, 2022Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split
To develop a targeted drug that prevents chemotherapy-induced side effects to help patients fight cancer more effectively with a better quality of lifeOUR VISION:
To bring chemoprotection to all patients with p53-mutated cancer regardless of the type of cancer or chemotherapy